Avacta's AVA6000 Shows Early Efficacy in Salivary Gland Cancers, Safety Profile Improves
Event summary
- Avacta presented updated Phase 1a/1b data for AVA6000 at ASCO 2026, showing 4 partial and 9 minor responses in 38 evaluable salivary gland cancer patients.
- Safety profile improved with no severe cardiac toxicity, leading to removal of the lifetime maximum doxorubicin limit.
- Disease control rate remained at 92%, with 9 patients continuing treatment and 11 in follow-up.
- PK data showed lower systemic exposure and delayed release of doxorubicin, reducing cardiac risk.
The big picture
Avacta's AVA6000 represents a novel approach to tumor-activated drug delivery, aiming to reduce systemic toxicity while maintaining efficacy. The positive early data positions the company favorably in the competitive oncology space, where safety and targeted delivery are increasingly critical. The removal of the lifetime maximum doxorubicin limit could significantly expand the drug's potential patient population and commercial appeal.
What we're watching
- Clinical Progression
- Whether the encouraging early efficacy signals in salivary gland cancers will translate into successful Phase 2 trials.
- Safety Validation
- The impact of the improved safety profile on regulatory approval timelines and dosing flexibility.
- Market Differentiation
- How Avacta's pre|CISION® platform will compete against traditional antibody drug conjugates in the oncology space.
Related topics